Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia

Overview of attention for article published in Leukemia & Lymphoma, December 2021

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

twitter: 5 X users

Readers on

mendeley: 19 Mendeley

So far, Altmetric has seen 7 X posts from 5 X users, with an upper bound of 5,110 followers.

RT @robweinkove: Haematologists are trained to focus on lab results, yet for chronic conditions quality of life (QoL) is key. In this analy…

Haematologists are trained to focus on lab results, yet for chronic conditions quality of life (QoL) is key. In this analysis of two @ALLGtrials in MDS/low blast AML, we found haemoglobin (not neutrophil or platelet count) is the key determinant of QoL …

Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia #lymphoma #lymsm https://t.co/MmGWlRZ9sd

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 3 additional X posts.